论文部分内容阅读
从人骨骼肌纯化醛缩酶（ＡＬＤ）Ａ，制备抗人ＡＬＤ－Ａ单克隆抗体，首次建立了测定血清ＡＬＤ－Ａ的竞争性ＥＬＩＳＡ，最小检出量０．１ｎｇ／ｍｌ，对ＡＬＤ－Ｂ和Ｃ无交叉反应。６０例正常人血清含量１３１±２４ｎｇ／ｍｌ，上限１７９ｎｇ／ｍｌ，均未超过此限；原发性肝细胞癌４５例５５４±１９３ｎｇ／ｍｌ，阳性率９５．５％（４４／４５），两组差异有非常显著意义（Ｐ＜０．００１）。对肝癌诊断有实用价值。单抗可大量制备，能使ＡＬＤ－Ａ检测标准化。
The aldolase (ALD) A was purified from human skeletal muscles to prepare anti-human ALD-A monoclonal antibodies. A competitive ELISA for the determination of serum ALD-A was established for the first time. The minimum detectable amount was 0.1 ng/ml for ALD-B. No cross reaction with C. 60 normal subjects had serum levels of 131±24 ng/ml and the upper limit of 179 ng/ml, which did not exceed this limit. 45 cases of primary hepatocellular carcinoma were 554±193 ng/ml, and the positive rate was 95.5% (44/45). The group difference was very significant (P < 0.001). Diagnosis of liver cancer has practical value. Monoclonal antibodies can be prepared in large quantities and can standardize ALD-A detection.